{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:08:49Z","timestamp":1790089729118,"version":"4.0.1"},"reference-count":25,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"2","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extracorporeal photopheresis (ECP) is a technology to treat chronic lung allograft dysfunction (CLAD) following lung transplantation. CLAD leads to significantly higher mortality rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to develop an early economic model that can evaluate the potential cost-effectiveness of treatments for patients with a confirmed diagnosis of CLAD and to evaluate a plausible cost-effectiveness range for ECP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The literature was reviewed and clinical experts were consulted to develop a Markov model with change in percent forced expiratory volume in 1 second (%FEV1) states, defining rates of lung function decline. The literature and clinical experts were also consulted to determine plausible transition probabilities between %FEV1 states and resource use. Probabilities of dying were estimated by calibrating the model to published survival curves. Treatment response was obtained from cohort studies. EQ-5D values and unit costs were obtained from published sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base case analysis, the incremental cost-effectiveness ratio (ICER) estimates for ECP ranged from \u00a333\u2009343\/QALY to \u00a388\u2009278\/QALY. This does not account for risk of bias in the implicit relative risk estimate in the model or for scenario combinations. The ICER was lower in the bronchiolitis obliterans syndrome population than in the restrictive allograft syndrome population and in earlier CLAD stages. The ICER was lower if ECP was provided for a course of treatment and there was a persistent protective effect from lung function decline after cessation of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusion\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was very little quality evidence to inform the decision model. The results included a wide range of ICERs. Key determinants include the therapeutic benefit of ECP after treatment cessation, response rates with standard care, and CLAD stage mortality rates.The economic model can be updated as new evidence emerges from ongoing clinical trials. For the National Institute of Health and Care Excellence in England, ECP may qualify as a highly specialized technology, for which the cost-effectiveness threshold may be \u00a3100\u2009000\/QALY or higher.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.163450","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:57:41Z","timestamp":1790089061000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":0,"title":["Early Economic Model of Extracorporeal Photopheresis and Other Treatments of Chronic Lung Allograft Dysfunction After Lung Transplantation"],"prefix":"10.36469","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-0813","authenticated-orcid":true,"given":"Stephen","family":"Rice","sequence":"first","affiliation":[{"name":"Newcastle University, UK","department":["Population Health Sciences Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diarmuid","family":"Coughlan","sequence":"additional","affiliation":[{"name":"Newcastle University, UK","department":["Population Health Sciences Institute"]},{"name":"Centre for Reviews and Dissemination, University of York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Vale","sequence":"additional","affiliation":[{"name":"Newcastle University, UK","department":["Population Health Sciences Institute"]},{"name":"Centre for Reviews and Dissemination, University of York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Cohen","sequence":"additional","affiliation":[{"name":"Axispharma Ltd on behalf of Therakos Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Benden","sequence":"additional","affiliation":[{"name":"University of Zurich Medical Faculty, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bennett","sequence":"additional","affiliation":[{"name":"University Hospital of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Greer","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvir","family":"Parmar","sequence":"additional","affiliation":[{"name":"Royal Papworth Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Tissot","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, Nantes, France","department":["Service de Pneumologie, l\u2019institut du thorax, Center for Research in Transplantation and Translational Immunology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Vos","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, Belgium","department":["Department of Respiratory Diseases, Lung Transplant and Respiratory Intermediate Care Unit"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam A.","family":"Perez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahond, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carby","sequence":"additional","affiliation":[{"name":"Royal Brompton and Harefield Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Thompson","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Santhanakrishnan","sequence":"additional","affiliation":[{"name":"Manchester University Foundation Trust, Wythenshawe Hospital, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Newcastle University, UK","department":["Translational and Clinical Research Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.15171\/ijhpm.2020.17","article-title":"The potential for early health economic modelling in health technology assessment and reimbursement decision-making","volume":"10","author":"H. Kim","year":"2021","journal-title":"Int J Health Policy Manag"},{"key":"ref2","article-title":"NICE health technology evaluations: the manual","author":"NICE","year":"2023"},{"key":"ref3","article-title":"BMC","author":"P. A. Fisher","year":"2023"},{"issue":"2","key":"ref4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.healun.2018.10.006","article-title":"Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction","volume":"38","author":"J. L. Todd","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11136-019-02340-4","article-title":"Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease","volume":"29","author":"C. Esquinas","year":"2020","journal-title":"Qual Life Res"},{"key":"ref6","article-title":"2021\/22 National Cost Collection Data Publication","author":"N. England","year":"2023","journal-title":"NHS England"},{"key":"ref7","article-title":"British National Formulary (BNF)","author":"NICE","year":"2023"},{"key":"ref8","article-title":"Drugs and pharmaceutical electronic market infromation tool (eMIT)","author":"GOV.UK","journal-title":"Department of Health and Social Care"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/14017431.2020.1726444","article-title":"Incidence and impact of chronic lung allograft dysfunction after lung transplantation - single-center 14-year experience","volume":"54","author":"A. Nykanen","year":"2020","journal-title":"Scand Cardiovasc J"},{"issue":"12","key":"ref10","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.healun.2021.08.007","article-title":"Economic evaluations and costing studies of lung transplantation: a scoping review","volume":"40","author":"J. K. Peel","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"ref11","article-title":"Estimated number of lung transplantations worldwide in 2022, by region","author":"Statista"},{"issue":"4","key":"ref12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s1053-2498(00)00251-5","article-title":"A model for analyzing the cost of the main clinical events after lung transplantation","volume":"20","author":"L. D. Sharples","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"ref13","article-title":"NICE-Wide Topic Prioritisation: The Manual","author":"NICE","year":"2024"},{"key":"ref14","article-title":"Therakos internal data","author":"Therakos","year":"2024"},{"issue":"3","key":"ref15","doi-asserted-by":"publisher","first-page":"e22128","DOI":"10.1002\/jca.22128","article-title":"Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction","volume":"39","author":"F. Gautschi","year":"2024","journal-title":"J Clin Apher"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ije\/dyy013","article-title":"Data maturity and follow-up in time-to-event analyses","volume":"47","author":"V. Gebski","year":"2018","journal-title":"Int J Epidemiol"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2023.2167442","article-title":"Projecting overall survival in health-economic models: uncertainty and maturity of data","volume":"39","author":"S. Roze","year":"2023","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"ref18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.healun.2018.07.020","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Lung and Heart-Lung Transplant Report\u20132018","volume":"37","author":"D.C. Chambers","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"ref19","article-title":"Annual Report on Lung Transplantation 2023\/24","author":"NHS Blood and Transplant","year":"2024"},{"key":"ref20","article-title":"Rapport m\u00e9dical et scientifique 2023","author":"Agence de la Biom\u00e9decine"},{"issue":"5","key":"ref21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","article-title":"Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment\u2013a consensus report from the Pulmonary Council of the ISHLT","volume":"38","author":"G. M. Verleden","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"ref22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1183\/09031936.00107514","article-title":"An international ISHLT\/ATS\/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome","volume":"44","author":"K. C. Meyer","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"e13281","DOI":"10.1111\/ctr.13281","article-title":"Comprehensive outcomes after lung retransplantation: a single-center review","volume":"32","author":"K. Halloran","year":"2018","journal-title":"Clin Transplant"},{"issue":"1","key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-001995","article-title":"Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK)","volume":"11","author":"A. J. Fisher","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"11551","DOI":"10.3389\/ti.2023.11551","article-title":"A European multi-center analysis of extracorporeal photopheresis as therapy for chronic lung allograft dysfunction","volume":"36","author":"A. Benazzo","year":"2023","journal-title":"Transpl Int"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/163450-early-economic-model-of-extracorporeal-photopheresis-and-other-treatments-of-chronic-lung-allograft-dysfunction-after-lung-transplantation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:57:42Z","timestamp":1790089062000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/163450-early-economic-model-of-extracorporeal-photopheresis-and-other-treatments-of-chronic-lung-allograft-dysfunction-after-lung-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.163450","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}